By annette
The Swedish Institute for Health Economics (IHE) and the Bengt Jönsson Foundation for Health Economics Research are hereby pleased to announce the recipient of the scholarship for this year’s student thesis in health economics. Read more
By annette
The IHE Type 2 Diabetes Cohort Model (IHE-DCM-T2) is frequently used to estimate cost-effectiveness of interventions for type 2 diabetes in different parts of the world. The model has recently been updated to include Japan. Läs mer
By annette
I3LUNG leads the way towards personalized oncology through artificial intelligence For the third consecutive year, Michael Willis, Research Director at IHE alongside the other partners of the I3LUNG consortium, an EU-funded project under the Horizon 2020 programme, have gathered for their annual meeting to share progress and reinforce their position as pioneers in the application …
By annette
The results for Portugal from the Cancer Comparator Report 2025 were presented at the conference Oncology 2030 – Innovation Challenges in the Fight Against Cancer organized by APIFARMA – Portuguese Pharmaceutical Industry Association. Some findings: Portugal has the 8th highest cancer incidence rate and the 9th highest cancer mortality rate in Europe. Spending on cancer …
By annette
The launch of the Cancer Comparator Report 2025 has created a lot of interest in Latvia. The uptake of new cancer medicines in Latvia is the lowest in the EU. Despite improvements in cancer survival over the last two decades, patients in Latvia still face challenges in accessing care on the same level as European …
By annette
At the 2025 ASCO Annual Meeting, IHE presents a poster on “The development of the cost of cancer in 31 European countries”, authored together with Dr. Christer Svedman and Prof. Nils Wilking. Poster synopsis: Cancer poses a significant economic burden on societies. This cost-of-illness study estimated the direct and indirect costs of cancer across 31 …
By annette
The Swedish Institute for Health Economics welcomes a new colleague, Urška Košir, as the new Project Manager in cancer policy.
By annette
A new registry-based study from IHE has evaluated if clinical outcomes and health-related quality of life (HRQoL) in Parkinson’s disease differ depending on whether patients meet the so-called 5-2-1 criteria. The criteria, which are based on motor symptoms, aim to identify patients with insufficient symptom control from oral medication. The results indicate a higher disease …
By annette
IHE participates at the conference with a poster presentation on the importance of using the right prices in the U.S., tailoring your analysis to the question at hand. Poster presentation Tailoring Generalized Cost-Effectiveness Analysis (GCEA) to the U.S. Setting: The Importance of Using the Right Prices Name of authors: Willis Michael, Nilsson Andreas and Neslusan Chery Name …
By annette
This IHE report questions the accuracy and reliability of using standardized drug administration tariffs from publicly available price lists, such as the Southern Healthcare Region’s Price List (SSPL) in Sweden, in health economic evaluations. These tariffs include unrelated costs (such as the drugs themselves, accounting for up to 76% of the total cost), lack granularity, …